A Single Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK586529 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2017
At a glance
- Drugs GSK 586529 (Primary)
- Indications Anxiety disorders; Major depressive disorder
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 22 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2008 New trial record.